Anti-citrullinated SR-A Peptide (Anti-csp) Antibody as a Biomarker in Rheumatoid Arthritis (RA).
Anti-Citrullinated SR-A Peptide (Anti-csp)Antibody as a Biomarker for Rheumatoid Arthritis.
1 other identifier
observational
81
0 countries
N/A
Brief Summary
- 1.To measure serum level of anticitrullinated SR-A peptide antibody (anti-CSP) in RA patients compared to healthy controls .
- 2.To assess the diagnostic performance of anti-CSP for RA specifically seronegative RA patients.
- 3.To evaluate correlation of serum anti-CSP level with disease activity and functional disability scores in RA patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 9, 2025
CompletedFirst Posted
Study publicly available on registry
August 28, 2025
CompletedStudy Start
First participant enrolled
January 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2027
August 28, 2025
July 1, 2025
1.9 years
August 9, 2025
August 26, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
To assess the diagnostic performance of anti-Citrullinated SR-A peptide antibody (anti-csp) for rheumatoid arthritis specifically seronegative rheumatoid arthritis patients .
through study completion, an average of 1 year
To evaluate correlation of serum anti-CSP level with disease activity and functional disability scores in RA patients .
through study completion, an average of 1 year
Study Arms (2)
27 seropositive patients according to results of rheumatoid factor and anticitrullinated antibodies.
27 seronegative patients according to results of rheumatoid factor and anticitrullinated antibodies.
27 seronegative patients according to results of RF and ACCP
Eligibility Criteria
Seronegative and seropositive rheumatoid arthritis patients and health control group
You may qualify if:
- Adults (≥18 years old)
You may not qualify if:
- Patients with other autoimmune or connective tissue diseases (e.g., SLE, SS) .
- Patients with chronic infections or malignancies .
- Patients less than18 years old .
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Xie Y, Wei C, Fu D, Zhang W, Du Y, Huang C, Liu S, Yao R, He Z, Zhang S, Jin X, Shen B, Cao L, Wang P, Fang X, Zheng X, Lin H, Wei X, Lin W, Bai M, Zhu D, Li Y, Ding Y, Zhu H, Ye H, He J, Su Y, Jia Y, Wu H, Wang Y, Xing D, Qiu X, Li Z, Hu F. Large-scale multicenter study reveals anticitrullinated SR-A peptide antibody as a biomarker and exacerbator for rheumatoid arthritis. Sci Adv. 2025 Jan 3;11(1):eadr8078. doi: 10.1126/sciadv.adr8078. Epub 2025 Jan 3.
PMID: 39752500BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Assistant Lecturer
Study Record Dates
First Submitted
August 9, 2025
First Posted
August 28, 2025
Study Start
January 1, 2026
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2027
Last Updated
August 28, 2025
Record last verified: 2025-07